Cancers最新文献

{"title":"Hemorrhagic PitNets Are Associated with Previous Vascular Events and Result in Worse Endocrine Outcome.","authors":"Harold F Hounchonou, Josef M Lang, Katja Döring, Christoph Terkamp, Holger Leitolf, Shadi Al-Afif, Elvis J Hermann, Christian Hartmann, Joachim K Krauss","doi":"10.3390/cancers16234105","DOIUrl":"https://doi.org/10.3390/cancers16234105","url":null,"abstract":"<p><strong>Background: </strong>Pituitary apoplexy is a potentially life-threatening condition that most often results from hemorrhage into a preexisting pituitary neuroendocrine tumor (PitNet) presenting with acute headache, visual impairment and endocrine dysfunction. Here, we aimed to identify factors associated with hemorrhage and present the pituitary hormonal status before and after transnasal-transsphenoidal tumor removal in a comparative study design.</p><p><strong>Methods: </strong>A series of 100 patients with PitNet were analyzed. We compared demographic data (age, sex, BMI), comorbidities, tumor volume and neuropathological findings between patients who presented with hemorrhagic PitNet (H-PitNet) and those with non-hemorrhagic PitNet (NH-PitNet). Furthermore, we compared the axis-specific hormonal status between both groups at admission and after microsurgical tumor removal and analyzed the overall endocrine outcome in both groups.</p><p><strong>Results: </strong>A total of 22 patients presented with hemorrhagic PitNet. There were no differences in age, sex, BMI, tumor volume, smoking status or diabetes status between patients with H-PitNet and those with NH-PitNet. H-PitNet was strongly associated with necrotic areas (<i>p</i> < 0.0001). Corticotropic PitNet was slightly overrepresented in H-PitNet (<i>p</i> = 0.04). Arterial hypertension was more frequent in patients with H-PitNet (<i>p</i> = 0.009). The presence of hypopituitarism in each axis at admission and after surgery was comparable between the two groups. In total, there were fewer recovering axes (<i>p</i> = 0.03) and more axes with persistent deficiency (<i>p</i> = 0.01) in the H-PitNet group after surgery.</p><p><strong>Conclusions: </strong>H-PitNet is associated with previous vascular event (ischemia or hemorrhage) and the presence of arterial hypertension and results in worse endocrine outcome. Early surgery should be considered in patients with PitNet and arterial hypertension.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aptamer's Structure Optimization for Better Diagnosis and Treatment of Glial Tumors.","authors":"Anastasia A Koshmanova, Polina V Artyushenko, Irina A Shchugoreva, Victoriya D Fedotovskaya, Natalia A Luzan, Olga S Kolovskaya, Galina S Zamay, Kirill A Lukyanenko, Dmitriy V Veprintsev, Elena D Khilazheva, Tatiana N Zamay, Daria A Ivanova, Maria R Kastyuk, Ivan N Lapin, Valery A Svetlichnyi, Felix N Tomilin, Nikita A Shved, Valeriia S Gulaia, Vadim V Kumeiko, Maxim V Berezovski, Anna S Kichkailo","doi":"10.3390/cancers16234111","DOIUrl":"https://doi.org/10.3390/cancers16234111","url":null,"abstract":"<p><p><b>Background:</b> Oncological diseases are a major focus in medicine, with millions diagnosed each year, leading researchers to seek new diagnostic and treatment methods. One promising avenue is the development of targeted therapies and rapid diagnostic tests using recognition molecules. The pharmaceutical industry is increasingly exploring nucleic acid-based therapeutics. However, producing long oligonucleotides, especially aptamers, poses significant production challenges. <b>Objectives:</b> This study aims to demonstrate the efficacy of using molecular modeling, supported by experimental procedures, for altering aptamer nucleotide sequences while maintaining their binding capabilities. The focus is on reducing production costs and enhancing binding dynamics by removing nonfunctional regions and minimizing nonspecific binding. <b>Methods:</b> A molecular modeling approach was employed to elucidate the structure of a DNA aptamer, Gli-55, facilitating the truncation of nonessential regions in the Gli-55 aptamer, which selectively binds to glioblastoma (GBM). This process aimed to produce a truncated aptamer, Gli-35, capable of forming similar structural elements to the original sequence with reduced nonspecific binding. The efficiency of the truncation was proved by flow cytometry, fluorescence polarization (FP), and confocal microscopy. <b>Results:</b> The molecular design indicated that the new truncated Gli-35 aptamer retained the structural integrity of Gli-55. In vitro studies showed that Gli-35 had a binding affinity comparable to the initial long aptamer while the selectivity increased. Gli-35 internalized inside the cell faster than Gli-55 and crossed the blood-brain barrier (BBB), as demonstrated in an in vitro model. <b>Conclusions:</b> The success of this truncation approach suggests its potential applicability in scenarios where molecular target information is limited. The study highlights a strategic and resource-efficient methodology for aptamer development. By employing molecular modeling and truncation, researchers can reduce production costs and avoid trial and error in sequence selection. This approach is promising for enhancing the efficiency of therapeutic agent development, particularly in cases lacking detailed molecular target insights.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the Benefits of Oral Cancer Screening: Challenges and Opportunities.","authors":"Francesca Farina, Nicola Cirillo","doi":"10.3390/cancers16234110","DOIUrl":"https://doi.org/10.3390/cancers16234110","url":null,"abstract":"<p><p>Screening is widely believed to facilitate early detection and improve health outcomes; however, recent evidence questions its overall benefits, highlighting the need for a critical assessment of cancer screening programs. The simplicity of clinical oral examination and the easy accessibility of the oral cavity make oral cancer a suitable candidate for opportunistic screening. Despite this uniqueness, studies that solidly assess the efficacy and cost-effectiveness of oral cancer screening are scanty, and the only large randomized trial undertaken so far shows limited evidence of mortality reduction through population screening. Research indicates that while early detection rates following screening may increase, they do not necessarily translate into decreased oral cancer deaths. This article emphasizes the need for a nuanced understanding of the benefits of screening, awareness of deceptive metrics and inherent biases in the context of early detection, and the importance of improving dentist education and introducing new technologies to enhance clinical decision-making. The review calls for a balanced and evidence-based approach to oral cancer screening, integrating it with broader oral health initiatives to maximize public health outcomes.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatectomy with Celiac Axis Resection and Reconstruction for Locally Advanced Pancreatic Cancer.","authors":"Satoshi Mizutani, Nobuhiko Taniai, Makoto Sukegawa, Takahiro Haruna, Hiroyasu Furuki, Hideyuki Takata, Junji Ueda, Masato Yoshioka, Takayuki Aimoto, Shunichiro Sakamoto, Kenji Suzuki, Yoshiharu Nakamura, Hiroshi Yoshida","doi":"10.3390/cancers16234115","DOIUrl":"https://doi.org/10.3390/cancers16234115","url":null,"abstract":"<p><strong>Background: </strong>With the advent of effective chemotherapy, conversion surgery (CS) has been performed in patients who have responded to pretreatment, even for pancreatic cancer diagnosed as unresectable (UR) at the time of initial diagnosis. In CS, major arterial resection and reconstruction are necessary for complete radical resection.</p><p><strong>Methods: </strong>We discuss the key points for safely performing pancreatectomy with celiac axis (CA) resection combined with reconstruction, divided into resection and arterial reconstruction. The possibility of safe pancreatectomy concurrent with CA resection and reconstruction depends on the ability to create a \"golden view\" that provides an unimpaired view of the Abdominal Aorta, CA, Superior Mesenteric Artery, Inferior Vena Cava, and left renal vein from the ventral side. Pancreatectomy concurrent with CA resection requires arterial reconstruction. Postoperatively, arterial blood flow must be maintained. To achieve this, tension-free and short bypass should be observed.</p><p><strong>Results: </strong>From 2014 to 2024, sixteen URLA patients underwent CS, requiring major artery en bloc resection after pretreatment. We performed DP-CAR in eight patients, gastrectomy-distal pancreatectomy-splenectomy (Appleby procedure) procedure in one patient, PD-CHAR in two patients, PD-CAR in two patients, TP-CAR(spleen preserving) in one patient, and TP-CAR+TG in two patients. In total, five patients required surgery with CA reconstruction. Histopathologically, four of the five patients had T4 pancreatic cancer. The R0 surgical rate was 80%. Complication of Clavien-Dindo IIIa or higher was observed in one patient. There were no deaths.</p><p><strong>Conclusions: </strong>Parallel to the determination of pretreatment, surgeons must be prepared to safely and reliably perform pancreatectomies that require concurrent major arterial resection and reconstruction.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.","authors":"Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, Francesca Sofia Di Lisa, Antonio Astone, Claudia Cutigni, Jennifer Foglietta, Martina Nunzi, Rosalinda Rossi, Mauro Minelli, Icro Meattini, Luca Visani, Jacopo Scialino, Lorenzo Livi, Luca Moscetti, Paolo Marchetti, Andrea Botticelli, Ida Paris, Francesco Pavese, Tatiana D'Angelo, Valentina Sini, Simonetta Stani, Maria Rosaria Valerio, Antonino Grassadonia, Nicola Tinari, Marco Mazzotta, Matteo Vergati, Giuliana D'Auria, Teresa Gamucci, Loretta D'Onofrio, Simona Gasparro, Arianna Roselli, Alberto Fulvi, Gianluigi Ferretti, Andrea Torchia, Monica Giordano, Filippo Greco, Francesco Pantano, Giuseppe Tonini, Agnese Fabbri, Emilio Bria, Giovanna Garufi, Elena Fiorio, Mimma Raffaele, Mirco Pistelli, Rossana Berardi, Rosa Saltarelli, Ramy Kayal, Francesca Romana Ferranti, Katia Cannita, Azzurra Irelli, Nicola D'Ostilio, Costanza De Rossi, Raffaella Palumbo, Anna Cariello, Giuseppe Sanguineti, Fabio Calabrò, Laura Pizzuti, Maddalena Barba, Claudio Botti, Fabio Pelle, Sonia Cappelli, Flavia Cavicchi, Ilaria Puccica, Amedeo Villanucci, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici","doi":"10.3390/cancers16234104","DOIUrl":"https://doi.org/10.3390/cancers16234104","url":null,"abstract":"<p><strong>Background/objectives: </strong>HER2-positive breast cancer (HER2⁺BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2⁺BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting. The secondary objective was to assess the effectiveness.</p><p><strong>Methods: </strong>This was a multicenter, retrospective study across 24 Italian oncology centers, including 410 patients with HER2⁺BC treated with adjuvant T-DM1 following a lack of pCR after NAT. Patient characteristics, NAT regimens, and surgical outcomes were recorded. Tolerability was assessed by documenting adverse events (AEs) according to the CTCAE (v5.0). Preliminary effectiveness was evaluated in terms of relapse-free survival (RFS) and overall survival (OS).</p><p><strong>Results: </strong>Overall, 228 patients (55.6%) experienced at least one AE related to T-DM1, with 4.9% experiencing grade 3 or higher AEs. The most common AEs were hepatotoxicity (18.5%) and thrombocytopenia (17.6%). T-DM1 was discontinued in 10.0% of patients due to toxicity. After a median follow-up of 25 months, 31 relapse events (7.6%) and 22 deaths (5.4%) were reported. The preliminary incidence of RFS and OS events was similar between patients who completed the T-DM1 course and those who discontinued it early.</p><p><strong>Conclusions: </strong>T-DM1 demonstrated a manageable safety profile, and the adverse events were consistent with those reported in randomized trials. The data are not yet sufficient to allow for a formal analysis of RFS and OS, and long-term follow-up is required.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Tumor Laterality and Focality on Clinical Implications and Tumor Advancement in Well-Differentiated Thyroid Cancer.","authors":"Michał Miciak, Krzysztof Jurkiewicz, Anna Dziekiewicz, Szymon Biernat, Michał Kisiel, Beata Wojtczak, Dorota Diakowska, Krzysztof Kaliszewski","doi":"10.3390/cancers16234109","DOIUrl":"https://doi.org/10.3390/cancers16234109","url":null,"abstract":"<p><strong>Background: </strong>The accurate preoperative diagnosis of TC plays a very important role in the selection of an appropriate treatment strategy. In addition to the hypoechogenicity of thyroid lesions on ultrasound and the presence of microcalcifications or high cell atypia on FNAB, highlighting the features of laterality and focality and ascertaining their influence (alone or combined) on TC staging and appropriate treatment are crucial.</p><p><strong>Materials and methods: </strong>A retrospective analysis of the clinical data of 697 patients admitted to the study center between 2008 and 2023 was conducted. Preoperative data (age, sex, type of surgery, ultrasound, and FNAB data) and postoperative histopathological data indicating TC advancement (pTNM, extrathyroidal extension, vascular invasion) were collected and analyzed. Patients presenting well-differentiated TCs (papillary TC and follicular TC) were isolated for better clinical evaluation. Finally, patients were divided into four groups according to their laterality and focality features, and the influences of combinations of these features on TC advancement were analyzed.</p><p><strong>Results: </strong>The largest group included patients with unilateral and solitary TC (<i>n</i> = 461). This group had the lowest rate of negative prognostic features: extrathyroidal extension, lymph node invasion, distant metastases, and vascular invasion (25.81%, 19.96%, 3.69%, and 26.46%, respectively). In contrast, the group with bilateral and multifocal TC (<i>n</i> = 40) presented the highest percentages of the mentioned features (82.50%, 82.50%, 7.50%, and 77.50%, respectively). All the results were statistically significant (<i>p</i> < 0.0001).</p><p><strong>Conclusions: </strong>Laterality and focality features may be important parameters in the management of TC and should be accurately determined. These features should be combined and a more aggressive treatment method should be selected to reduce the reoperation rate.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Imaging in Multiple Myeloma: A Potential Opportunity for Quantitative Imaging and Radiomics?","authors":"Anna Michalska-Foryszewska, Aleksandra Rogowska, Agnieszka Kwiatkowska-Miernik, Katarzyna Sklinda, Bartosz Mruk, Iwona Hus, Jerzy Walecki","doi":"10.3390/cancers16234099","DOIUrl":"https://doi.org/10.3390/cancers16234099","url":null,"abstract":"<p><p>Multiple myeloma (MM) is the second most prevalent hematologic malignancy, particularly affecting the elderly. The disease often begins with a premalignant phase known as monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma (SP) and smoldering multiple myeloma (SMM). Multiple imaging modalities are employed throughout the disease continuum to assess bone lesions, prevent complications, detect intra- and extramedullary disease, and evaluate the risk of neurological complications. The implementation of advanced imaging analysis techniques, including artificial intelligence (AI) and radiomics, holds great promise for enhancing our understanding of MM. The integration of advanced image analysis techniques which extract features from magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) images has the potential to enhance the diagnostic accuracy for MM. This innovative approach may lead to the identification of imaging biomarkers that can predict disease prognosis and treatment outcomes. Further research and standardized evaluations are needed to define the role of radiomics in everyday clinical practice for patients with MM.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desmoplastic Small Round Cell Tumors of the Gastrointestinal Tract.","authors":"Jeffrey Gonzalez, Stephanie Ocejo, Mercy Iribarren, Alvaro Abreu, Hisham F Bahmad, Robert Poppiti","doi":"10.3390/cancers16234101","DOIUrl":"https://doi.org/10.3390/cancers16234101","url":null,"abstract":"<p><p>Desmoplastic small round cell tumors (DSRCTs) of the gastrointestinal (GI) tract are a rare and highly aggressive variant of soft tissue sarcomas, predominantly affecting the abdominal region. These tumors are believed to originate from multipotent mesenchymal stem cells or primitive progenitor cells. They are composed of small round tumor cells associated with prominent stromal desmoplasia, polyphenotypic differentiation, and <i>EWSR1::WT1</i> gene fusion. Diagnostically, DSRCTs present a significant challenge due to their histological resemblance to other small round cell tumors, such as Ewing sarcoma and rhabdomyosarcoma, necessitating the use of ancillary tests, including immunopanels and molecular analysis, to reach a definitive diagnosis. Immunohistochemical staining, including markers like cytokeratin, vimentin, desmin, and WT1, has proven valuable in differentiating DSRCTs from their mimickers. The prognosis of these tumors is highly dependent on factors such as tumor location and stage at diagnosis, and given their aggressive nature, a multidisciplinary approach may be required that combines surgical resection, chemotherapy, and radiation therapy, among other options. In this review, we provide a synopsis of the pathophysiology of DSRCTs and the latest diagnostic advancements, including the utility of molecular profiling and novel biomarkers.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer.","authors":"Isabella Frigerio, Quoc Riccardo Bao, Elisa Bannone, Alessandro Giardino, Gaya Spolverato, Giulia Lorenzoni, Filippo Scopelliti, Roberto Girelli, Guido Martignoni, Paolo Regi, Danila Azzolina, Dario Gregori, Giovanni Butturini","doi":"10.3390/cancers16234106","DOIUrl":"https://doi.org/10.3390/cancers16234106","url":null,"abstract":"<p><strong>Objective: </strong>To build a Bayesian approach-based model to predict the success of surgical exploration post-neoadjuvant treatment.</p><p><strong>Background: </strong>Pancreatic cancer (PDAC) is best treated with radical surgery and chemotherapy, offering the greatest chance of survival. Surgery after neoadjuvant treatment (NAT) is indicated in the absence of progression, knowing the limits in accurately predicting resectability with traditional radiology. R Status being a pathological parameter, it can be assessed only after surgery.</p><p><strong>Method: </strong>Patients successfully resected for histologically confirmed PDAC after NAT for BR and LA disease were included, with attention to the predictors of R status from the existing literature. The Bayesian logistic regression model was estimated for predicting the R1 status. The area under curve (AUC) of the average posterior probability of R1 was calculated and results were reported considering the 95% posterior credible intervals for the odds ratios, along with the probability of direction.</p><p><strong>Results: </strong>The final model demonstrated a commendable AUC value of 0.72, indicating good performance. The likelihood of positive margins was associated with older age, higher ASA score, the presence of venous and/or arterial involvement at preoperative radiology, tumor location within the pancreatic body, a lack of tumor size reduction post-NAT, and the persistence of an elevated Ca19.9 value.</p><p><strong>Conclusions: </strong>A Bayesian approach using only preoperative items is firstly used with good performance to predict R Status in pancreatic cancer patients who underwent resection after neoadjuvant therapy.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Biomechanics-Inspired Future Medicine.","authors":"Yuqing Dong, Mengnan Lu, Yuting Yin, Cong Wang, Ningman Dai","doi":"10.3390/cancers16234107","DOIUrl":"https://doi.org/10.3390/cancers16234107","url":null,"abstract":"<p><p>Malignant tumors pose a significant global health challenge, severely threatening human health. Statistics from the World Health Organization indicate that, in 2022, there were nearly 20 million new cancer cases and 9.7 million cancer-related deaths. Therefore, it is urgently necessary to study the pathogenesis of cancer and explore effective diagnostic and treatment strategies. In recent years, research has highlighted the importance of mechanical cues in tumors, which have become a new hallmark of cancer and a key factor in regulating tumor behavior. This suggests that studying the mechanical properties of tumors may open potential new avenues for understanding the pathogenesis, diagnosis, and therapeutic intervention of cancer. This review summarizes the mechanical characteristics of tumors and the development of tumor diagnostics and treatments targeting specific mechanical factors. Finally, we propose new ideas and insights for the application of mechanomedicine in cancer diagnosis and treatment in the future.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}